
Analysis
Healthtech funding rebounds to $1.1 billion in Q3 as investors return to diagnostics
Late-stage rounds are back, but investors are writing cheques for profitability, not growth at any cost.
Rohan Malhotra6 min read

Patient-specific implants could cut surgery times and reduce revision rates, the company says.
8 min read

The deals give the company more than 30,000 clinic customers and set up a likely IPO filing next year.
8 min read

The Series B will fund regulatory filings and a push into district hospitals where neurologists are scarce.
6 min read

High customer-acquisition costs are pushing app makers towards enterprise contracts.
8 min read

From AI pathology to rural pharmacies, our editors pick the young companies with the most momentum.
7 min read